1. Myomo will present at the H.C. Wainwright 27th Annual Conference. 2. Management will conduct virtual one-on-one investor meetings at the event. 3. Myomo's MyoPro product enhances functionality for those with upper-limb paralysis. 4. The MyoPro device is the only marketed solution using patient EMG signals. 5. Myomo aims to improve patients' independence and reduce care costs.
Engagement in significant investment conferences often leads to increased investor interest, mirroring trends observed in past events for tech firms showcasing innovations.
The conference presence indicates strategic positioning and possible investor interest, which can be pivotal for MYO's near-term market perception and performance.
Immediate investor engagement during the conference may yield short-term price reactions, akin to movements seen during similar events in other tech sectors.
Myomo, Inc. (NYSE:MYO) ("Myomo" or the "Company"), a wearable medical robotics company that offers increased functionality for those suffering from neurological disorders and upper-limb paralysis, today announced that Paul Gudonis, president and chief executive officer, and David Henry, chief financial officer, will present at the H.C. Wainwright 27th Annual Global Investment Conference taking place September 8-10, 2025 at the Lotte New York Palace Hotel. A Company presentation will be available on demand for conference participants and management will be available for virtual one-on-one meetings with investors registered for the event.
Investors interested in scheduling a meeting with the Company should contact their H.C. Wainwright representative, or email meetings@hcwco.com.
About Myomo
Myomo, Inc. is a wearable medical robotics company that offers improved arm and hand function for those suffering from neurological disorders and upper-limb paralysis. Myomo develops and markets the MyoPro product line. MyoPro is a powered upper-limb orthosis designed to support the arm and restore function to the weakened or paralyzed arms of certain patients suffering from CVA stroke, brachial plexus injury, traumatic brain or spinal cord injury or other neuromuscular disease or injury. It is currently the only marketed device in the U.S. that, sensing a patient's own EMG signals through non-invasive sensors on the arm, can restore an individual's ability to perform activities of daily living, including feeding themselves, carrying objects and doing household tasks. Many are able to return to work, live independently and reduce their cost of care. Myomo is headquartered in Burlington, Massachusetts, with sales and clinical professionals across the U.S. and representatives internationally. For more information, please visit www.myomo.com.
View source version on businesswire.com: https://www.businesswire.com/news/home/20250902766120/en/
Myomo:
ir@myomo.com
Alliance Advisors IR:
Tirth T. Patel
tpatel@allianceadvisors.com
212-201-6614